Senti Biosciences Inc (SNTI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.38M
Last updated: Nov 17, 2026 at 4:44 PM ET
Senti Biosciences Inc (SNTI) Statistics
Senti Biosciences (SNTI) has a market cap of $5.38M and an enterprise value of $6.13M. It kept -58140.54% of revenue as net income over the last 12 months. Revenue fell 98.74% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 13.82% above the market cap, as debt exceeds cash.
| Market Cap | $5.38M |
|---|---|
| Enterprise Value | $6.13M |
| Latest price (Nov 17, 2026) | $0.10 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 14, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 40.8x.
| P/S Ratio | 40.8x |
|---|---|
| Forward P/S | 107.7x |
Price Statistics
The stock is down 93.98% over 52 weeks and trades 60.00% below its 50-day average.
| Beta (1Y) | 2.48 |
|---|---|
| 52-Week Change | -93.98% |
| 1-Month Change | -57.23% |
| 3-Month Change | -79.05% |
| 6-Month Change | -88.98% |
| 5-Year Change | -99.84% |
| Total Return (1Y) | -93.98% |
| Total Return (3Y CAGR) | -71.11% |
| Total Return (5Y CAGR) | -75.06% |
| Max Drawdown (1Y) | -95.94% |
| Max Drawdown (3Y) | -99.03% |
| Sharpe Ratio (1Y) | -2.46 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $0.25 |
| 200-Day Average | $0.67 |
| 52-Week Range | $0.13 to $2.48 |
| RSI (14 Days) | 25.1 |
| Average Volume (20 Days) | 8.84M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.54x current liabilities.
| Current Ratio | 0.54x |
|---|---|
| Quick Ratio | 0.54x |
Returns and Efficiency
Return on invested capital is 1039.76% over the last 12 months.
| Return on Assets (ROA) | -151.71% |
|---|---|
| Return on Invested Capital (ROIC) | 1039.76% |
| ROA (5Y Average) | -64.55% |
| Asset Turnover | 0.00x |
| Receivables Turnover | 0.11x |
Scores
SNTI has an Altman Z-Score of -24.47, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -24.47 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $74.00K over the last 12 months.
| Revenue | $74.00K |
|---|---|
| Revenue Growth (YoY) | -98.74% |
| Gross Profit | $74.00K |
| Operating Income | -$50.06M |
| Pretax Income | -$43.23M |
| Net Income | -$43.02M |
| EBITDA | -$40.63M |
| Reported EPS (TTM) | -$1.77 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $5.55M |
|---|---|
| Total Debt | $6.30M |
| Net Debt | $744.00K |
| Net Debt Per Share | $0.02 |
| Working Capital | -$8.07M |
| Shareholder Equity | -$9.60M |
| Total Assets | $28.36M |
| Total Liabilities | $37.96M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$35.33M |
|---|---|
| FCF Per Share | -$0.92 |
| Depreciation and Amortization | $2.90M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -67652.70%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -67652.70% |
| Pretax Margin | -58417.57% |
| Net Margin | -58140.54% |
| EBITDA Margin | -54901.35% |
Growth
Revenue fell 82.75% a year over 3 years.
| Revenue Growth (3Y CAGR) | -82.75% |
|---|---|
| Revenue Growth (5Y CAGR) | -43.85% |
| Book Value Per Share Growth (2Y CAGR) | -59.27% |
| Tangible Book Per Share Growth (2Y CAGR) | -59.27% |
Dividends and Yields
SNTI does not pay a dividend.
| Buyback Yield | -347.06% |
|---|---|
| Shareholder Yield | -347.06% |
Stock Splits
The last split was a 1-for-10 reverse split on Jul 18, 2024.
| Last Split Date | Jul 18, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 5 similar companies, SNTI has the highest ROIC.
ROICPeer median -150.11%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| ROIC | 1039.76% vs -150.11% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -98.74% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 50.76% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +50.76% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SNTI
What is SNTI's market cap?
Senti Biosciences has a market cap of $5.38M. Its enterprise value, which adds debt and subtracts cash, is $6.13M.
How many shares of SNTI are outstanding?
Senti Biosciences has 31.15M shares outstanding. The count is up 18.75% from a year earlier.
Does SNTI pay a dividend?
No. Senti Biosciences does not pay a dividend.
How much debt does SNTI have?
Senti Biosciences has $6.30M of total debt and $5.55M of cash and equivalents, a net debt position of $744.00K.
SNTI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors